Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

• Published in: Diabetes care Vol. 45; no. 3; pp. 650 - 658
• Main Authors: Palanca, Ana, van Nes, Falco, Pardo, Felipe, Ampudia Blasco, F. Javier, Mathieu, Chantal
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.03.2022
• Subjects: Adult; Adults; Adverse events; Albumins; Creatinine; Demography; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - chemically induced; Diabetes Mellitus, Type 1 - drug therapy; Diabetic ketoacidosis; Diabetic Ketoacidosis - chemically induced; Epidermal growth factor receptors; Evaluation; Glomerular filtration rate; Humans; Hypoglycemia; Hypoglycemic Agents - adverse effects; Inhibitor drugs; Insulin; Insulin - adverse effects; Ketoacidosis; Ketosis; Na+/glucose cotransporter; Renal function; Retrospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Subgroups; Weight loss
• ISSN: 0149-5992; 1935-5548; 1935-5548
• DOI: 10.2337/dc21-1584

To evaluate real-world efficacy and safety of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in combination with insulin in people with type 1 diabetes. We conducted a retrospective cohort European two-center study. Data on demographics, HbA1c, weight, insulin use, renal function, and adverse...